Page last updated: 2024-09-04

ezetimibe and Neoplasms

ezetimibe has been researched along with Neoplasms in 16 studies

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (50.00)29.6817
2010's8 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L1
Frikke-Schmidt, R; Kobberø Lauridsen, B; Nordestgaard, BG; Stender, S; Tybjærg-Hansen, A1
Basta, N; Bolin, K; Busch-Sørensen, M; Egstrup, K; Emneus, M; Green, A; Iachina, M; Kent, C; Kesäniemi, YA; McNally, R; Pedersen, TR; Ramey, DR; Ray, S; Stavem, K; Willenheimer, R1
Baigent, C; Califf, R; Clare, R; Collins, R; Emberson, J; Landray, M; Peto, R1
Curfman, GD; D'Agostino, RB; Drazen, JM; Morrissey, S; Ware, JH1
Boman, K; Brudi, P; Chambers, JB; Egstrup, K; Gerdts, E; Gohlke-Bärwolf, C; Holme, I; Kesäniemi, YA; Malbecq, W; Nienaber, CA; Pedersen, TR; Ray, S; Rossebø, AB; Skjaerpe, T; Wachtell, K; Willenheimer, R1
Fleming, TR1
Cox, A1
Nissen, SE1
Blazing, MA; Califf, RM; Harrington, RA1
Nissen, SE; Taylor, AJ1
Drazen, JM; Wood, AJ1
Kim, PS; Rosenblatt, M1
Boyden, T; Khanderia, U; Regal, RE; Rubenfire, M1
Prasad, V; Vandross, A1

Reviews

2 review(s) available for ezetimibe and Neoplasms

ArticleYear
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
    Nature cell biology, 2015, Volume: 17, Issue:11

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction

2015
The ezetimibe controversy: implications for clinical practice.
    Therapeutic advances in cardiovascular disease, 2011, Volume: 5, Issue:4

    Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Plaque, Atherosclerotic

2011

Trials

2 trial(s) available for ezetimibe and Neoplasms

ArticleYear
Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial.
    The American journal of cardiology, 2014, Nov-15, Volume: 114, Issue:10

    Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Neoplasms; Registries; Retrospective Studies; Risk Assessment; Simvastatin; Survival Rate; Time Factors

2014
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
    The New England journal of medicine, 2008, Sep-25, Volume: 359, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticholesteremic Agents; Aortic Valve Stenosis; Aspartate Aminotransferases; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Bypass; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Kaplan-Meier Estimate; Male; Neoplasms; Simvastatin; Treatment Outcome

2008

Other Studies

12 other study(ies) available for ezetimibe and Neoplasms

ArticleYear
Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer.
    International journal of epidemiology, 2017, 12-01, Volume: 46, Issue:6

    Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Denmark; Ezetimibe; Female; Genetic Variation; Humans; Hypercholesterolemia; Male; Membrane Proteins; Membrane Transport Proteins; Mendelian Randomization Analysis; Middle Aged; Neoplasms; Proportional Hazards Models; Risk Assessment; Risk Factors

2017
Analyses of cancer data from three ezetimibe trials.
    The New England journal of medicine, 2008, Sep-25, Volume: 359, Issue:13

    Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Humans; Hypercholesterolemia; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Simvastatin

2008
Ezetimibe and cancer--an uncertain association.
    The New England journal of medicine, 2008, Sep-25, Volume: 359, Issue:13

    Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Simvastatin

2008
Identifying and addressing safety signals in clinical trials.
    The New England journal of medicine, 2008, Sep-25, Volume: 359, Issue:13

    Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Simvastatin

2008
Hypercholesterolaemia: Clarifications from adverse drug reactions agency.
    BMJ (Clinical research ed.), 2008, Sep-16, Volume: 337

    Topics: Anticholesteremic Agents; Azetidines; England; Ezetimibe; Humans; Hypercholesterolemia; Neoplasms; Risk Factors; Simvastatin; United States; United States Food and Drug Administration

2008
Analyses of cancer data from three ezetimibe trials.
    The New England journal of medicine, 2009, Jan-01, Volume: 360, Issue:1

    Topics: Anticholesteremic Agents; Azetidines; Data Interpretation, Statistical; Ezetimibe; Humans; Hypercholesterolemia; Neoplasms; Randomized Controlled Trials as Topic; Risk

2009
Premature release of data from clinical trials of ezetimibe.
    The New England journal of medicine, 2009, Aug-13, Volume: 361, Issue:7

    Topics: Adverse Drug Reaction Reporting Systems; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Databases as Topic; Drug Approval; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Registries; Simvastatin; United States

2009
Preliminary observations from preliminary trial results: have we finally had enough?
    Circulation. Cardiovascular quality and outcomes, 2008, Volume: 1, Issue:1

    Topics: Adult; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cardiovascular Surgical Procedures; Ezetimibe; Heart Failure; Humans; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Reperfusion Injury; Research Design; Simvastatin; Survival Analysis; Treatment Outcome

2008
Don't mess with the DSMB.
    The New England journal of medicine, 2010, Jul-29, Volume: 363, Issue:5

    Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cardiovascular Diseases; Clinical Trials Data Monitoring Committees; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hypoglycemic Agents; Neoplasms; Rosiglitazone; Simvastatin; Thiazolidinediones; United States

2010
Ezetimibe: excess cancer incidence in a comparative trial.
    Prescrire international, 2010, Volume: 19, Issue:107

    Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Humans; Incidence; Neoplasms

2010
More on DSMBs.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Drug Industry; Ezetimibe; Humans; Neoplasms; Simvastatin; United States

2011
Cardiovascular primary prevention: how high should we set the bar?
    Archives of internal medicine, 2012, Apr-23, Volume: 172, Issue:8

    Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Industry; Evidence-Based Medicine; Ezetimibe; Fenofibrate; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Mass Screening; Neoplasms; Niacin; Primary Prevention; Randomized Controlled Trials as Topic; Simvastatin

2012